Role of the microenvironment in myeloid malignancies

Marie Goulard1 · Christine Dosquet1,2 · Dominique Bonnet3

Received: 8 August 2017 / Revised: 1 December 2017 / Accepted: 5 December 2017 / Published online: 8 December 2017
© The Author(s) 2017. This article is an open access publication

Abstract
The bone marrow microenvironment (BMM) regulates the fate of hematopoietic stem cells (HSCs) in homeostatic and pathologic conditions. In myeloid malignancies, new insights into the role of the BMM and its cellular and molecular actors in the progression of the diseases have started to emerge. In this review, we will focus on describing the major players of the HSC niche and the role of the altered niche function in myeloid malignancies, more specifically focusing on the mesenchymal stroma cell compartment.

Keywords Bone marrow niche · Myeloid malignancies · Leukemic-initiating cells · Mesenchymal stroma cells

Introduction
The HSCs, the cell population capable of reconstituting the entire blood system, have been highlighted for the first time by Till and McCulloch [1, 2]. Several functional techniques both in vitro and in vivo are able to demonstrate the presence of the HSCs. These techniques are indirect, proving the presence of the stem cells by their capacity of differentiation, i.e., in vitro, the colony forming cells (CFC) and the long-term culture-initiating cells (LTC-IC) assays [3].

The best proof of the presence of HSCs is the xenograft experiment: when injected in sub-lethally immunodeficient mice, the HSCs are capable of long-term reconstitution of the entire hematopoietic system and capable of repopulation into secondary recipient mice, thus proving their stem cell multi-lineage and self-renewal status [4].

The HSCs are located in BM “niches”. The concept of stem cell niches has been introduced for the first time by Schofield [5]. By studying CFU-S, he stated that the HSCs needed to be associated with other cells to determine their behavior. The niche concept is a way of explaining the dependence of HSCs to their microenvironment [6]. This concept implies that HSCs would not have the same self-renewing capacity without the support of the BMM cells. Niches are composed of cellular and molecular components that regulate the fate of the HSCs, i.e., quiescence, self-renewing capacities, differentiation and mobilization [7, 8]. More recently, the concept of the niche determining the fate of the HSC has been reexamined. Indeed, HSC fate has been proven to be highly specific, both in vivo and in vitro and defined by intrinsic epigenetic features [9]. The niche-restricted HSCs differentiation only to maintain their stem cell status, and thus having a permissive rather than instructive role [9]. Nevertheless, stroma modifications have been reported to contribute to abnormal hematopoiesis such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)-like disease (see paragraph: mouse models to study the role of BMM in myeloid malignancies). Thus, these studies represent strong evidence that the microenvironment exerts more than a mere by standard effect in myeloid malignancies. The relationship between the niche and the malignant clone(s) has reactivated the concept of the “bad seed in the bad soil” theory proposed in 1889, by Stephen Paget, an English surgeon, to describe how bad environment (“the soil”) of tumor cells (“the seeds”) could favor metastasis development [10, 11].
Normal bone marrow microenvironment

The bone marrow microenvironment (BMM) is a complex cellular and molecular entity composed of mesenchymal stroma cells (MSC), endothelial cells, nerves from the sympathetic nervous system, accessory cells (T lymphocytes and monocytes), etc. that plays a role in BM homeostasis (see Fig. 1). This cellular and molecular microenvironment regulates the HSCs quiescence, their self-renewal and their differentiation via cellular interactions and paracrine effects [7]. MSCs play a central role in the interactions with HSCs. Vascularization plays also a major role in the BM. There are two types of blood vessels: the fenestrated sinusoids in the endosteum and the medulla, and the arterioles in the endosteum.

Fig. 1 The normal bone marrow microenvironment. The HSCs' fate is regulated by a specific microenvironment in the BM: the niches. The endosteal niche is commonly described close to the endosteum and is composed of osteoblasts and osteoclasts. The vascular niche is in the central zone of the bone, close to the sinusoids. Several types of cells compose these niches: the MSCs (LepR⁺ cells, CAR cells, nestin⁺ cells and CD146⁺ cells), the endothelial cells, the megakaryocytes, the adipocytes and the sympathetic nervous system (SNS). Several couples of molecules are implicated in the HSCs fate: particularly CXCL12–CXCR4, SCF—c-kit, angiopoietin 1 (Ang-1)—Tie-2, thrombopoietin (TPO)—MPL and osteopontin (OPN)—αvβ2 integrin
BMM is hypoxic displaying a decreasing gradient of oxygen between the BM sinusoids and the bone remodeling units (6–1%) [7, 8], due to the dense vascularity of the center-medullary zone of the BM. Hypoxia is inducing HIF-1α and hypoxia-inducible factor (HIF-2α), essential factors for the long-term self-renewing of the HSCs [12]. There is also a high concentration of calcium ion (Ca^{2+}) in the endosteal region due to bone remodeling [13]. In this microenvironment, the cross-talk between MSCs and HSCs is imperative for the homeostasis of adult BM.

A number of cytokines, cytokine receptors and adhesion molecules have been implicated in the cross-talk between HSCs and cells of the BMM, particularly CXCL12 (SDF-1)—CXCR4, SCF (stem cell factor)—c-kit, vascular cell adherence molecule 1 (VCAM1)—VLA-4 (α4β2), angiopoietin-1 (Ang-1) and Tie-2, thrombopoietin (TPO)—MPL [14]. In vitro studies showed that the BMM cells, notably the osteoblasts secrete hematopoietic cytokines such as CXCL12, SCF, Ang-1 IL-6 and Jagged 1 (Jag1, Notch ligand) [15, 16]. SCF and IL-6 support normal hematopoiesis but also the maintenance and quiescence of HSCs. SCF is principally expressed by the perivascular cells in the BM [17]. Ang-1 regulates HSCs quiescence and has an anti-apoptotic effect [14]. TGFβ1 (transforming growth factor β1) has also been demonstrated to induce HSCs quiescence [18]. Osteopontin (OPN) is a glycoprotein synthesized by osteoblasts in the endosteal region that recognizes the integrin αvβ1 on the HSC surface and plays a role in cell adhesion, inflammatory responses and angiogenesis. OPN also plays a role in the localization, proliferation and mobilization of HSCs [19]. A mouse model of OPN deficient mice shows that OPN retains the HSCs in the BM and regulates negatively their number [20]. The osteoblasts express TPO at their surface that activates the cMPL receptor present at the surface of the hematopoietic stem and progenitor cells (HSPCs). This TPO/cMPL interaction induces the quiescence of the stem cells via activation of the β-integrin pathway [21].

The endosteal and vascular niches

Usually two types of niches are described: the endosteal niche and the vascular niche but these niches are tightly linked anatomically and functionally inside the trabecular bone [7, 22, 23]. The HSCs niches are dynamic structures responding to physiological demands. In general, the closer the HSCs are to the endosteum, the more quiescent they are [23–25], proliferative HSCs being mostly located in the central zone of the BM.

The endosteal niche is located closer to the bone surface and mainly plays a role in the quiescence of the HSCs. The main actors of the HSCs regulation in this niche are the osteoblasts and osteoblastic progenitors. The osteoblasts are distributed along the endosteal surface of the bone. They are in close proximity to the vessels [24, 25]. In a transgenic mouse model with PTH/PTHrP receptors activated in the osteoblasts, the increase number of these cells was associated with an increased number of HSCs, and HSCs cell growth in the endosteal region of the BM [15]. The osteoblast cells support the HSCs and influence their functions through Notch activation. Notch inhibition induces a decrease in the number of HSCs in the endosteal region [26]. The inactivation of the bone morphogenetic protein receptor (BMP) in another mouse model was shown to increase the number of osteoblasts and HSCs. The cell-to-cell contact between the HSCs and the osteoblasts is mostly mediated by N-cadherin and β-catenin [15, 27].

The vascular niche was first described as supporting the proliferation and differentiation of HSCs but there is now evidence of quiescent HSCs in the vicinity of sinusoids [17]. A study shows that nearly 85% of the long-term repopulating HSPCs are close to sinusoids [28]. In this zone, the HSCs are in contact with leptin receptor (Lepr+), CXCL12high cells [28] and endothelial cells who promote their maintenance [17]. The HSCs are physically close to the sinusoids and distant from the arterioles [28]. The Lepr+ cells are surrounding the sinusoids. NG2+ cells, or polydendrocytes, are close to the arterioles in the endosteum, and play also a role in the maintenance of the HSPCs. The depletion of NG2+ cells induces HSCs proliferation and exhaustion of HSCs pool [29].

The mesenchymal stromal cells (MSCs)

In 1867, Cohnheim described for the first time, particular non-hematopoietic cells in the bone marrow capable of regeneration. It is only in 1970, that Dr. Friedenstein described the isolation of (MSC) [30] which has been described to be in close proximity of the HSCs within the BM [31] and were later isolated using the Stro-1 antibody [32]. Nowadays, the mesenchymal stromal/stem cells are defined by the International Society of Cellular Therapy (ISCT) by their capacity of adhesion to plastic; their capacity to differentiate toward adipogenic, osteogenic and chondrogenic pathways and their specific phenotype [33]. The MSCs are described as a heterogeneous group of cells sharing the same positive and negative phenotype: CD73+, CD90+, CD105+ and CD34−, CD31−, CD45RA−, CD14−, CD19−, HLA-DR−. These criteria allow the standardization of MSCs characterization.

The MSCs are rare elements in the BM (0.01%) [34] but play a major role in the relationship between the BMM and the HSCs, in particular the CAR cells (CXCL12-abundant reticular cells), the nestin+ cells and the CD146+ cells [35]. The origin of the MSCs in the adult BM are the LeprR+ (leptin receptor) cells. The LeprR+ cells represent 0.3% of the...
cells in the BM and are quiescent but proliferate under stress [36].

The CD146+ cells are a subtype of MSCs mostly located in the human vascular niche. They represent 3% of the mononuclear cells inside the BM. The CD146+ cells express Ang-1 and CXCL12 and interact with HSCs and endothelial cells by their expression of Tie-2 and CXCR4 [37].

The nestin+ cells are mostly perivascular. They represent 0.08% of the mononuclear cells inside the BM and derive from the neural crest [37]. The nestin+ cells are also associated with nerves from the sympathetic nervous system (SNS) [35, 38]. This specific type of MSCs supports the homing and reduces the mobility of HSCs. The nestin+ cells also regulate the quiescence of HSCs via a high expression of maintenance genes: CXCL12, SCF, Ang1, IL-7, VCAM-1 [37]. In vitro, the nestin+ cells lose rapidly the nestin at their surface because of cell differentiation.

The CAR cells are more abundant than the nestin+ MSCs (0.27%). This type of MSCs is mostly located in the endosteal region of the BM. The CAR cells regulate the cell cycle and the self-renewing of the HSCs via a high expression of CXCL12 and SCF. It seems that most quiescent HSCs are in close contact with CAR cells [39]. This function has been confirmed in an in vivo model of CXCL12 silencing in the CAR cells [40]. In this model, the number of HSPCs is decreased. The CAR cells control the proliferation and the maintenance of the HSC pool [10, 41].

**Endothelial cells**

MSCs and HSCs are in close contact with the endothelial cells in the BM. Several evidences point out the key role of the endothelial cells in the regulation of the HSCs in the BM niche. In a mouse model with disruption of VEGFR2 and VE-cadherin, a decreased number of HSPCs, with more differentiated cells was observed [42]. A deletion of E-selectin at the surface of endothelial cells promotes the quiescence of the HSPCs [43]. In this Sele−/− mouse model, BrdU assay shows reduced HSCs turnover—more than 30% of HSC in G0 phase—compared to wild type or P-selectin knockout mice. These studies suggest clearly that the endothelial cells participate to the proliferation and quiescence of the HSCs.

**Other cells, actors of the HSCs niche**

Several other cell types play a major role in the regulation of the HSCs fate in the BMM such as the megakaryocytes, the adipocytes, nerves from the SNS and macrophages. The megakaryocytes are associated with the vascular niche, are in tight contact with HSCs and regulate their proliferation through various cytokines (IGFBP-3, IGF-1). They also regulate the HSCs quiescence by secreting platelet factor 4 (PF4—CXCL4) [44, 45]. In a mouse model, the absence of megakaryocytes leads to a loss of HSCs quiescence and enhances differentiation [45]. The role of megakaryocytes in the HSCs quiescence is also mediated by TGFβ1 contained in their α-granules together with PF4 [46].

The adipocytic tissue in the BM has a mesenchymal origin [47]. Several evidences point to the fact that the adipocytic cells support the HSCs maintenance and proliferation in their niche by producing the adipokine and adiponectin [48]. Interestingly, the number of adipocytes is inversely proportional to the number of HSCs and their decrease enhances the HSCs engraftment [49]. A recent study has shown that the adipocytic cells inhibit hematopoiesis and BM regeneration via the release of dipeptidyl peptidase 4 (DPP4 or CD26), a protein associated with apoptosis and immune response [50].

The sympathetic nervous system (SNS) is implicated in the mobilization of HSCs in the BM [51]. The BM neurons are β-adrenergic nerve terminals [51, 52]. The SNS is composed of non-myelinating Schwann cells that regulate the niche by activation of TGFβ1 [52]. The SNS regulates CXCL12 expression by perivascular BMM cells and HSCs retention via the circadian oscillation [53, 54].

The macrophages have been described as important elements of the BM niche. In a mouse model, the deletion of CD169+ cells (macrophages) is deleterious for the retention of the HSPCs by the niche [55]. The macrophages express also CXCL12 and osteocalcin [56] and are capable of modulating the CXCL12 expression by MSCs [55, 57] leading to the retention of the HSCs in the niche and to support the survival of osteoblasts. The use of granulocyte colony-stimulating factor (G-CSF) decreases the number of osteoblastic cells and depletes the macrophages in the endosteum [57], suggesting that macrophages support the osteoblasts in the retention of the HSCs.

**BMM in myeloid disorders**

**Mouse models to study the effect of BMM in malignant development**

Mouse models have been used to better understand the progression of myeloid malignancies and particularly the role of the BMM in their natural history. A mouse model of Osx-GFP-Cre+ Dicer1 flox/flox mice suggests that a modification of the BMM could in itself induce MDS [58]. In this model, the deletion of Dicer1 gene in osteoprogenitors leads to an impaired hematopoiesis mimicking human MDS. In the osteoprogenitors of these mice, the expression of the Shwachman–Diamond–Bodian (SBDS) gene decreases. Moreover, KO SBDS mice display a MDS phenotype too. In a mouse model with a deletion of SBDS gene, the MSCs display non-functioning mitochondria associated with higher
oxidative stress and DNA damage in the HSCs, suggesting a possible role of the stroma in the development of a myeloid disease [59].

In an acute myeloid leukemia (AML) mouse model, the overactivation of the β-catenin pathway via overexpression of a constitutive active mutation of β-catenin in osteoblasts reduces the differentiation potential of myeloid and lymphoid progenitors, leading to MDS/AML progression [60]. In these osteoblastic cells, overexpressing beta-catenin the authors revealed an upregulation of NOTCH ligand Jagged-1. They went on to demonstrate that in human AML BM biopsies, a nuclear-activated β-catenin in osteoblasts and elevated Notch signaling in hematopoietic cells providing evidence of the potential relevance of these results in human disease. Interestingly, the alteration of osteoblastic cells by activation of the PTH receptor in BCR-ABL induced mouse model of chronic myeloid leukemia (CML), decreases CML disease but enhances MLL-AF9 induced AML development, demonstrating that distinct myeloid disease required different niches factors [61].

Several other mouse models demonstrate the implication of the BMM in the development and progression of non-Philadelphia MPN. MPN disease was able to develop in a mouse model where deletion of the retinoblastoma (RB1) protein was introduced in both the hematopoietic compartment as well as the microenvironment [62]. In another study by the same group, a deletion of retinoic acid receptor gamma (RARγ) in the niche was sufficient to induce a MPN-like disease [63]. In another study, Ptpn11-activating mutation in the nestin+ MSCs but not in osteoblasts or endothelial cells, has a deleterious effect on HSCs and leads to MPN [64]. PTPN11-mutant MSCs overproduced CCL3, which recruited monocytes secreted IL1β and other proinflammatory cytokines to the HSC niche.

The number of nestin+ cells in the BM and the expression of nestin messenger were reduced in the BM of Jak2V617F mice, associated to expansion of leukemic initiating cells (LICs) and MPN progression [65]. In another murine model of MPN (Scl-tTA.TRE-BCR/ABL double transgenic mouse model), the influence of LICs on the microenvironment was associated with an increase in abnormal osteoblastic cells in the BM creating a myelofibrosis inflammatory environment. This “leukemic niche” promoted proliferation of LICs instead of normal HSCs, TGFβ and Notch pathways were implicated in this BM remodeling [66].

BMM modifications in patients with myeloid malignancies

In acute and chronic myeloid malignancies, the cross-talk of the neoplastic myeloid cells with the BMM plays an important role in the progression of the disease. In patients with myeloid neoplasia, there are morphological modifications of the BMM such as an increase of angiogenesis in patients with AML and MDS [67–69]. Similar angiogenesis and impair vascularity was also observed in AML-PDX model [70]. BM fibrosis is frequently observed in patients with non-Philadelphia MPN [71] and in patients with MDS [72].

In patients with myeloid malignancies, a possibility to approach the modifications of the BMM is to isolate and study the BM MSCs. Indeed, a number of studies suggest that functional modifications of the BM MSCs are related to the natural history of myeloid diseases such as AML, MDS, non-Philadelphia MPN and CML [73, 74].

Here, we choose to focus on the genetic, epigenetic, gene expression, clonogenic and differentiation capacities of the MSCs of patients with myeloid neoplasia as well as bone marrow failure syndrome exemplified by Aplastic anemia (see Fig. 2).

The BMM of aplastic anemia (AA)

Aplastic anemia is a BM failure, associated with a hypoplasia and peripheral pancytopenia. Changes in the BMM of AA patients have been reported. In BM biopsy from AA patients, an increase of stromal cells expressing osteopontin and a decrease of osteonectin expressing cells as well as endothelial cells have been described [75–77]. The AA BM has a decreased angiogenesis [77, 78] associated with a decrease of VEGF expression [79].

A number of studies have reported on AA MSCs, and showed that in general AA MSCs have either a normal or slightly decreased clonogenic potential compared to control [75, 80–82]. The AA MSCs are more inclined to enter apoptosis in vitro [75]. Studies on MSCs differentiation from AA patients are heterogeneous and do not allow us to conclude [75, 77, 83].

One study reported that AA MSCs have a reduce capacity to support a normal hematopoiesis in vitro [83]. But in a 3D in vivo scaffold, AA MSCs were capable to form a functional BM niche [81].

Several genes involved in biological processes such as proliferation, chemotaxis and interaction with HSCs are downregulated in AA MSCs [74]. VCAM-1 plays a crucial role in HSCs retention in the BMM and is particularly decreased in AA MSCs [83, 84]. AA MSCs secrete high levels of macrophage inflammatory protein 1 alpha (MIP-1alpha) and GM-CSF but low levels of IL-1Ra compared to healthy control MSCs [85]. This abnormal gene expression in AA MSCs could explain at least partly the abnormal HSCs regulation observed in AA patients.
The BMM of MDS

MDS constitute a heterogeneous group of clonal myeloid diseases with diverse phenotypes, characterized by ineffective hematopoiesis with varying risk of leukemic transformation. In vitro, MDS stromal cells were reported to be quantitatively and functionally impaired.

The results of cytogenetic analysis of MSCs from MDS patients are contradictory [86–89]. A study by Lopez-Villar reported no cytogenetic abnormalities in the MDS MSCs despite cytogenetic abnormalities in the HSCs [87]. Other studies reported abnormalities of karyotype in MSCs obtained from MDS patients [73, 88]. The corresponding HSCs also displayed abnormalities but none were similar to those observed in the corresponding MSCs. It is important to underline that MSCs are known to be genetically instable in culture [89]. MDS-MSCs have a different methylation profile than normal MSCs. An increase of the methylation in genes involved in processes linked to cellular phenotype and transcriptional regulation has been reported [90].
A large majority of these studies deals with ex vivo expanded MSCs. In cultured, MDS-MSCs modification of expression of various genes has been observed: such as cytokines [91–94], adhesion molecules [95] and molecules involved in the interaction with the HSCs such as OPN, Jagged1, Kit-L and Ang1 [90]. CXCL12 was reported to be overexpressed in MSCs of MDS patients [94, 96, 97].

A recent study of isolated mesenchymal elements sorted directly from low-risk MDS BM patients by the markers CD45−/7AAD−/CD235a−/CD31−/CD271+/CD105+ describes a different transcriptomic signature of MSCs from MDS patients in comparison with normal MSCs or cultured MDS-MSCs. The directly sorted uncultured MSCs have characteristics of cellular stress and upregulation of inflammation cytokines linked to inhibition of hematopoiesis [97]. Several studies demonstrated epigenetic and transcriptomic variations of cultured MDS MSCs. This was further confirmed in directly isolated mesenchymal elements compared to control MSCs with a specific increase in hypermethylation in enhancer regions [98, 99] and downregulation of pathways including the Wnt pathway [97, 100]. Interestingly, there were also differences both at the epigenetic and transcriptomic level, between the native sorted stromal elements and cultured MSCs clearly, indicating that 2D-cultured system used for expanded MSCs (normal or from patients) influence these cells [97, 100].

MDS-MSCs clonogenic potential was shown to be clearly decreased at diagnosis as demonstrated by CFU-F assays [88, 95, 97, 101, 102]. Similarly, the proliferative capacity of MDS-MSCs is also decreased, no matter the patient IPSS score [90, 95, 102, 103]. The MDS-MSCs enter senescence earlier than normal MSCs [104, 105] and display a senescent phenotype in vitro [97].

The MSCs differentiation data are heterogeneous. Some studies show no alterations of the differentiation capacity of the MDS MSCs [86, 91, 92, 101, 103, 106]. The adipogenic and chondrogenic pathways were reported as decreased in some studies [87, 107]. The osteogenic pathway is often reported as impaired in high-risk and low-risk MDS [102, 104, 108]. Genes linked to the osteogenitors and osteoblasts (Dicer, DROSHA, RUNX2 and SBDS) have been reported to have a weaker expression in the MDS-MSCs [58, 108, 109]. As suggested by a mouse model, the MSCs, especially those differentiating in the osteogenic pathway, could have a primary role in MDS development [58].

It has been demonstrated that MDS-MSCs have an impaired capacity to support a normal hematopoiesis in vitro [90, 94, 95, 102]. MDS-ICs have been reported to proliferate less when not co-cultured with their autologous MSCs [108]. When co-cultured with MDS-ICs, normal MSCs have a higher expression of LIF, VEGF, ANGPTL4 and CXCL12 than the non-co-cultured counterpart [96, 107].

In vivo, primary MDS cells engraft poorly in the immunodeficient mice [110]. A potential increase of MDS engraftment was reported when co-injected with either control or MDS MSCs in NSG-S mice (3/20 samples) [111]. Nevertheless, a recent study showed no difference of MDS engraftment in NSG or NSG-S mice when co-injected with MDS-MSCs [112]. Thus, the long-term effect of MDS-MSC on MDS engraftment is unclear, probably due to the fact that the implantation of MSCs (even after intra bone injection) in immunodeficient mice, do not really engraft long-term [112]. So far, there is no study using the 3D-scaffold model for MDS engraftment assessment in vivo.

The BMM of chronic MPN

Myeloproliferative neoplasms are a group of chronic myeloid diseases characterized by a BM hyperplasia of one or several myeloid lineages. Among MPNs are CML with Philadelphia chromosome and bcr-abl transcript and the non-Philadelphia MPN, i.e., polycythemia vera (PV), essential thrombocytemia (ET) and primitive myelofibrosis (PMF). The most common mutations in non-Philadelphia MPN are Jak2\(^V617F\), MPL\(^W515\) and CALR mutations.

Few studies focus on the MPN-MSCs ex vivo. MSCs derived from the BM of MF patients display the same clonogenicity as normal MSCs in CFU-F assay and MF-MSCs have also been reported to have a similar capacity to support normal hematopoiesis as normal MSCs [113].

Nevertheless, the remodeling of BMM is particularly visible in the BM biopsies of pre-fibrotic MPN patients: the CD271\(^+\) cells are decreased in the endosteal and vascular niches and are associated with dysplastic megakaryocytes [114]. Interestingly, a reduction in the number of sympathetic nerve fibers associated with the MSCs was reported in the BM of MPN patients [65].

The differentiation capacities of the MPN-MSCs seem to be impaired. Indeed, a report show in MF-MSCs, an increase capacity to differentiate into osteoblasts in vitro and to mineralize subcutaneous compared to normal MSCs and even MSCs derived from PV and ET patients [113]. In this study, this capacity was associated with an upregulation of Runx2, Dlx5, OPN and IBSP and a deregulated transcriptomic signature related to osteogenic lineage in MF-MSCs.

MPN-MSCs have also been shown to have a protecting role on LICs via paracrine secretion of IL-6, FGF and CXCL10 [115]. Two studies on PV patients report that the protecting role of MSCs against JAK2 inhibitor leading to a decrease in apoptosis of JAK2(V617F) mutated cells [115, 116]. In PMF patients, Jak2\(^V617F\) overactivates the complex CXCL12/CXCR4 via activation of the PI3K pathway and increases hematopoietic cells chemotaxis [116]. PV-MSCs overproduce fibrogenic and inflammatory cytokines such as...
TGF-β1 and BMP-2, which stimulate the osteogenic differentiation pathway [113, 117]. CD9 (tetraspanin 29) expression, known to be implicated in the HSCs interaction with the stroma, is decreased at the surface of CD34+ cells in PMF patients, this decrease being inversely correlated with fibrosis [118].

In a study using a 3D in vitro culture model, MPN-MSCs have been reported to have a decrease capacity to support HSCs and ET-MSCs to secrete lower levels of G-CSF and IL-17 [114]. In this study, the authors also reported an increased in fibronectin deposition by the MPN-MSCs, and confirmed this by tissue microarray of pre-fibrotic MPN-BM biopsies.

There are very few studies concerning CML-MSCs and their role in the CML BMM. A majority of studies have been done with stromal cell lines. The CML stromal cells have been reported to have a protective role on HSCs in vitro by decreasing their apoptosis [119], this role being mediated via the CXCR4/CXCL12 axis [120]. One study reported the presence of the same genetic aberration, particularly the fusion gene BCR-ABL, to be present in both the neoplastic clone and endothelial cells, suggesting that this molecular event occurred in hemangioblasts [121].

The BMM of AML

AML is a heterogeneous clonal disorder characterized by expansion of immature myeloid progenitors (blasts) in the BM and peripheral blood. Chromosomal aberrations are frequently observed in MSCs of untreated AML patients. The most frequent are translocations [73]. These aberrations are never identical to those found in the HSCs of the same patients. Sequencing DNA from AML-MSCs also highlighted numerous gene mutations including mutations in plectin and chromatin remodeling genes [122]. Modifications of DNA methylation were also described: hypermethylation of PITX2 and HOXB6 genes and hypomethylation of HOXA3 and HOXA5 genes [123]. Gene expression modifications were also reported for a large number of CD146−166+ osteoblastic cells were found in osteoblastic lineage such as osterix and osteocalcin [135]. A larger number of CD146−166+ osteoblastic cells were found in sections of BM of AML patients in comparison with normal BM [135]. Only in poor risk AML, Diaz de la Guardia et al., reported a decrease in adipose tissue and bone marrow, which is the site of origin of AML [135]. In two recent studies, AML-MSCs were reported to have a decrease in adipogenic and a parallel increase in osteo-lineage differentiation [137, 138]. In one of this study, they confirmed the decrease in adipogenesis in primary AML patients bone marrow and demonstrate that leukemic cells suppression of BM adipocytes led to an imbalance regulation of endogenous hematopoietic stem and progenitor cells, resulting in impaired myeloid-erythroid maturation [137]. In the second study, they show that AML-induced osteo-lineage differentiation support leukemic growth [138].

The MSCs ability to sustain hematopoiesis can be studied both in vitro, via co-culture models in 2D and 3D and in vivo via xenografts in immunodeficient mice. AML-MSCs LTC-IC’s data suggest an impaired capacity of these cells to support a normal hematopoiesis [124–126, 135]. Few myeloid colonies are observed in methylcellulose after LTC-IC culture of normal HSCs with AML-MSCs. In addition, MSCs derived from AML patients were reported to support LICs in vitro better than healthy MSCs [136, 139]. Very few xenograft experiments involve the co-injection...
of AML cells together with autologous MSCs, but when co-injected, the MSCs do not seem to improve the level of engraftment [140]. Subcutaneous scaffold injected with MSCs in vivo using matrigel, or other materials, have recently been described and shown to improve the rate of LICs grafted in mice [141–143]. Similarly, implantation of these scaffolds, seeded with healthy MSCs, improve the engraftment of normal HSCs [141, 142]. The engraftment in the scaffold is reduced if the MSCs used are knockout for Hif-1α [140]. Thus, these 3D scaffolds seem to mimic the human niche environment and improve engraftment of the leukemic cells [140–143].

Several data suggest that the BMM has a protective effect on the leukemic cells. The contact with MSCs protects the leukemic cells from apoptosis [127, 144] and from various chemotherapies [127, 145–147]. It also maintains their undifferentiated status [139], self-renewing capacities [148] and survival [127, 144]. In vitro, AML-MSCs displayed the same chemoprotection capacities than healthy MSCs but have higher immunosuppressive and anti-inflammatory properties with a diminution of pro-inflammatory cytokines expression [136]. The protective effect of MSCs is modulated by various cytokines including the axis CXCR4/CXCL12 [127, 132, 145, 146]. On the other hand, AML cells influence the microenvironment and decrease the proliferation of normal MSCs in co-culture [123]. This observation suggests a bi-directional cross-talk between the LICs and the BMM in patients with AML.

Discussion

Over the past decade, the contribution of different stroma cells to the maintenance of HSCs has started to emerge. A better understanding of the relationship between the HSCs/LICs and their microenvironment is a key to understand the natural history of myeloid neoplasia. Even though AA is a BM failure and not a myeloid malignancy, complication in AA can lead to secondary MDS or AML [149]. Thus, evaluating qualitatively and quantitatively the composition of the bone marrow stroma during the evolution of AA to MDS and AML and dissecting the differences at different malignant stages will be highly valuable to shed light into the specific role of certain microenvironment factors in myeloid malignancies and should help adapt therapeutics treatment targeting specifically the specific cross-talk between the malignant cells and their niche [150]. The difference in composition of the BM niche could also be possibly exploited as a potential clinical biomarker tool to predict response or relapse in clinical trial settings.

Drugs that disrupt adhesion of LICs from their protective niche have started to emerge in clinics such as CXCR4 and adhesion molecule (VCAM-1, VLA-4, E-selectin) inhibitors [150, 151 and see more details review 152]. As immunotherapy against MDS/AML are also expanding especially using different immune checkpoint inhibitors, the potential contribution of the stroma to immune escape to therapy resistance will have to be studied. Indeed, recently in pancreatic cancer, the CXCR4/CXCL12 axis has been linked to the resistance to immune checkpoint therapy [153]. Our understanding of the cellular composition of the normal, dysplastic, and leukemic niches and the complex interactions between these cells is still in its infancy. Nevertheless, targeting the deregulated niche and restoring niche function is already providing a promising new therapeutic rationale in myeloid malignancies.

Acknowledgements This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001045), The UK Medical Research Council (FC001045) and the Welcome Trust (FC001045). MG was supported by Minister of research, Paris Diderot University, France.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. McCulloch EA, Till JE (1960) The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res 13:115–125
2. Becker AJ, Mc CE, Till JE (1963) Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197:452–454
3. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ (1990) Functional characterization of individual hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 87(9):3584–3588
4. Doulatov S, Notta F, Laurenti E, Dick JE (2012) Hematopoiesis: a human perspective. Cell Stem Cell 10(2):120–136. https://doi.org/10.1016/j.stem.2012.01.006
5. Schofield R (1978) The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4(1):7–25
6. Schofield R (1983) The stem cell system. Biomed Pharmacother 37(8):375–380
7. Morrison SJ, Scadden DT (2014) The bone marrow niche for haematopoietic stem cells. Nature 505(7483):327–334. https://doi.org/10.1038/nature12984
8. Yu VW, Scadden DT (2016) Heterogeneity of the bone marrow niche. Curr Opin Hematol 23(4):331–338. https://doi.org/10.1016/j.cshem.2016.04.010
9. Baryawno N, Severe N, Scadden DT (2017) Hematopoiesis: reconciling historic controversies about the niche. Cell Stem Cell 20(3):590–592. https://doi.org/10.1016/j.stem.2017.03.025
10. Ribatti D, Mangialardi G, Vaccia A (2006) Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin Exp Med 6(4):145–149. https://doi.org/10.1007/s10238-006-0117-4
11. Le Bousse-Kerdiles MC (2012) Primary myelofibrosis and the “bad seeds in bad soil” concept. Fibrogenesis Tissue Repair 5(Suppl 1):S20. https://doi.org/10.1186/1755-1536-5-S1-S20
12. Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z, de Verneuil H, Gribben J, Taussig D, Revzani HR, Mazurier F, Bonnet D (2013) HIF-2alpha protects human hematopoietic stem/progenitors and acute myeloid leukemia cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell 13(5):549–563. https://doi.org/10.1016/j.stem.2013.08.011
13. Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT (2006) Stem cell engrafment at the endothelial niche is specified by the calcium-sensing receptor. Nature 439(7076):599–603. https://doi.org/10.1038/nature04247
14. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118(2):149–161. https://doi.org/10.1016/j.cell.2004.07.004
15. Calvi LM, Adams GB, Weinbrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Brinthurst FR, Milner LA, Kronenberg HM, Scadden DT (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425(6960):841–846. https://doi.org/10.1038/nature02040
16. Taichman RS, Emerson SG (1994) Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 179(5):1677–1682
17. Ding L, Saunders TL, Enikolopov G, Morrison SJ (2012) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 198(9):1232–1239. https://doi.org/10.1084/jem.20120440
18. Yamanaka S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H (2009) TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113(6):1250–1256. https://doi.org/10.1182/blood-2008-04-146480
19. Nilsson SK, Johnston HM, Whitby GA, Williams B, Webb RJ, Denhardt DT, Bertconello I, Bendall LJ, Simmons PJ, Haylock DN (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106(4):1232–1239. https://doi.org/10.1182/blood-2004-11-4422
20. Stier S, Ko Y, Forbret R, Lutz C, Neuhaus T, Grunewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT (2005) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201(11):1781–1791. https://doi.org/10.1084/jem.20041992
21. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R, Thoren LA, Ekkblom M, Alexander WS, Jacobsen SE (2007) Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 1(6):671–684. https://doi.org/10.1016/j.stem.2007.10.008
22. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425(6960):836–841. https://doi.org/10.1038/nature02414
23. Nilsson SK, Johnston HM, Coverdale JA (2001) Spatial localization of transplanted hematopoietic stem cells: inferences for the localization of stem cell niches. Blood 97(8):2293–2299
24. Coelho C, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujiyaki J, Cote D, Rowe DW, Lin CP, Scadden DT (2009) Live-animal tracking of individual hematopoietic stem/progenitor cells in their niche. Nature 457(7225):92–96. https://doi.org/10.1038/ nature07434
25. Xie Y, Yin T, Wiegaebe W, He XC, Miller D, Stark D, Perko K, Alexander R, Schwartz J, Grindley JC, Park J, Haug JS, Wunderlich JP, Li H, Zhang S, Johnson T, Feldman RA, Li L (2009) Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457(7225):97–101. https://doi.org/10.1038/nature07639
26. Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT (2002) Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 99(7):2369–2378
27. Sugimura R, He XC, Venkatraman A, Arai F, Box A, Semerad C, Haug JS, Peng L, Zhong XB, Suda T, Li L (2012) Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell 150(2):351–365. https://doi.org/10.1016/j.cell.2012.05.041
28. Acar M, Kocherlakota KS, Murphy MM, Peyer JG, Oguro H, Ina CN, Jayeola C, Zhao Z, Luby-Phelps K, Morrison SJ (2015) Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature 526(7571):126–130. https://doi.org/10.1038/nature15250
29. Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, Mizoguchi T, Wei Q, Lucas D, Ito K, Mar JC, Bergman A, Frenette PS (2013) Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502(7473):637–643. https://doi.org/10.1038/nature12612
30. Fridenstein AI, Petrakova KV, Kuralessova AL, Frolova GI (1968) Precursor cells for osteogenic and hematopoietic tissues. Tsitologiia 10(5):557–567
31. Lichtman MA (1981) The ultrastructure of the hemopoietic environment of the marrow: a review. Exp Hematol 9(4):391–410
32. Simmons PJ, Torok-Storb B (1991) Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78(1):55–62
33. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prokop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317. https://doi.org/10.1080/14653240600855905
34. Rasin V, Dominici M, Kluba T, Siegel G, Lusenti G, Northoff H, Horwitz EM, Schafer R (2013) Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy 15(3):292–306. https://doi.org/10.1080/14653240600855905
35. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Mac-arthur BD, Lira SA, Scadden DT, M’aja’an A, Enikolopov GN, Frenette PS (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829–834. https://doi.org/10.1038/nature09262
36. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ (2015) Leptin-receptor-expressing mesenchymal stem cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15(2):154–168. https://doi.org/10.1016/j.stem.2014.06.008
37. Iserrn J, Garcia-Garcia A, Martin AM, Arranz L, Martin-Perez D, Torroja C, Sanchez-Cabo F, Mendez-Ferrer S (2014) The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function. Elife 3:e03696. https://doi.org/10.7554/eLife.03696
38. Mendez-Ferrer S, Battista M, Frenette PS (2010) Cooperation of beta(2)- and beta(3)-adrenergic receptors in hematopoietic progenitor cell mobilization. Ann N Y Acad Sci 1192:139–144. https://doi.org/10.1111/j.1749-6632.2010.05390.x
39. Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell
40. Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, Nasagawa T (2010) The essential functions of adipocyte osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33(3):387–399. https://doi.org/10.1016/j.immuni.2010.08.017

41. Mendelsohn A, Frenette PS (2014) Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med 20(8):833–846. https://doi.org/10.1038/nm.3647

42. Butler JM, Nolan DJ, Vertes EL, Varrum-Finney B, Kobayashi H, Hooper AT, Sandel M, Shido K, White IA, Kobayashi M, Witte L, May C, Shawber C, Kimura Y, Kitajewski J, Rosenwaks Z, Bernstein ID, Rafii S (2010) Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6(3):251–264. https://doi.org/10.1016/j.stem.2010.02.001

43. Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki N, Norozi F, Shahrabi S, Hajizamani S, Saki N (2016) Regulatory role of megakaryocytes on hematopoietic stem cells quiescence by CXCL4/PF4 in bone marrow niche. Leuk Res 48:107–112. https://doi.org/10.1016/j.leukres.2015.12.012

44. Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki N, Scheiermann C, Schif F, Poncz M, Bergman A, Frenette PS (2014) Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med 20(11):1315–1320. https://doi.org/10.1016/j.molimm.2013.08.017

45. Zhao M, Perry JM, Marshall H, Venkatraman A, Qian P, He XC, Ahamed J, Li L (2014) Megakaryocytes maintain homeostatic quiesence and promote post-injury regeneration of hematopoietic stem cells. Nat Med 20(11):1321–1326. https://doi.org/10.1038/nm.3706

46. Berry R, Rodeheffer MS, Rosen CJ, Horowitz MC (2015) Adipose tissue residing progenitors (adipocyte lineage progenitors and adipose derived stem cells (ADSC). Curr Mol Biol Rep 1(3):101–109. https://doi.org/10.1007/s40610-015-0018-y

47. DiMascio L, Voermans C, Usqezwa M, Duncan A, Lu D, Wu J, Sangakari S, Roya T (2007) Identification of adiponectin as a novel hematopoietic stem cell growth factor. J Immunol 178(6):3511–3520. https://doi.org/10.4049/jimmunol.178.6.3511

48. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley ZC, Ahamed J, Li L (2014) Megakaryocytes maintain homeostatic quiesence and promote post-injury regeneration of hematopoietic stem cells. Nat Med 20(11):1321–1326. https://doi.org/10.1038/nm.3706

49. Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, Woelk L, Fan H, Logan DW, Schurmann A, Saraiva LR, Schul TJ (2017) Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoiesis and bone regeneration. Cell Stem Cell 20(6):771 e776–784 e776. https://doi.org/10.1016/j.stem.2017.02.009

50. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS (2006) Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124(2):407–421. https://doi.org/10.1016/j.cell.2005.10.041

51. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo MM, Karlsson S, Iwama A, Nakachuki H (2011) Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147(5):1146–1158. https://doi.org/10.1016/j.cell.2011.09.053

52. Lucas D, Battista M, Shi PA, Isola L, Frenette PS (2008) Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell 3(4):364–366. https://doi.org/10.1016/j.stem.2008.09.004

53. Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chevre R, Noelia AG, Kunisaki Y, Zhang D, van Rooijen N, Silberstein LE, Weber C, Nasagawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neuropilin clearance. Cell 153(5):1025–1035. https://doi.org/10.1016/j.cell.2013.04.040

54. Chow A, Lucas D, Hidalgo A, Mendez-Ferrer S, Hashimoto D, Scheiermann C, Battista M, Leboeuf M, Prophete C, van Rooijen N, Tanaka M, Merad M, Frenette PS (2011) Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 208(2):261–271. https://doi.org/10.1084/jem.20101688

55. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC (2011) Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 208(2):251–260. https://doi.org/10.1084/jem.20101700

56. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton J, van Rooijen N, Alexander KA, Raggatt LJ, Levesque JP (2010) Bone marrow macrophages maintain hematopoietic stem cell niche and their depletion mobilizes HSCs. Blood 116(23):4815–4828. https://doi.org/10.1182/blood-2009-11-253534

57. Raaijmakers MH, Muhkerjee S, Guo S, Zhang S, Kobayashi T, Schoomaker JA, Ebert BL, Al-Shahrour F, Hasseriyan RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens JM, Scadden DT (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464(7290):852–857. https://doi.org/10.1038/nature08851

58. Zambetti NA, Ping Z, Chen S, Kenswil KJ, Myllona MA, Sanders MA, Hoogenboezem RM, Bindels EM, Adisty MN, Van Strien PM, Van der Leij CS, Westers TM, Cremers EM, Milanese C, Mastroberardino PG, Van Leeuwen JP, Van der Eerden BC, Touw IP, Kuipers TW, Kanaar R, Van de Loosdrecht AA, Vogt T, Raaijmakers MH (2016) Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukaemia. Cell Stem Cell 19(5):613–627. https://doi.org/10.1016/j.stem.2016.08.021

59. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Gallil N, Muhkerjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S (2014) Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 506(7487):240–244. https://doi.org/10.1038/nature12883

60. Krause DS, Fulzeke K, Catic A, Sun CC, Dombkowski D, Hurley MP, Lezeau S, Attar E, Wu JY, Lin HY, Divieti-Pajevic P, Hasseriyan RP, Schipani E, Van Etten RA, Scadden DT (2013) Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 19(11):1513–1517. https://doi.org/10.1038/nm.3364

61. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH (2007) Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Nat Med 129(6):1081–1095. https://doi.org/10.1016/j.cell.2007.03.055

62. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE (2007) A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129(6):1097–1100. https://doi.org/10.1016/j.cell.2007.05.014

63. Dong L, Yu WM, Zheng H, Loh ML, Bunting ST, Pauly M, Huang G, Zhou M, Brommeyer HE, Scadden DT, Qu CK (2016) Leukaemogenic effects of Ptpn11 activating mutations in the
stem cell microenvironment. Nature 539(7628):304–308. https://doi.org/10.1038/nature20131
65. Arranz L, Sanchez-Aguilera A, Martin-Perez D, Isern J, Langa X, Tzankov A, Lundberg P, Munition S, Tzeng YS, Lai DM, Schwallier J, Skoda RC, Mendez-Ferrer S (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512(7512):78–81. https://doi.org/10.1038/nature13383
66. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegue E (2013) Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13(3):285–299. https://doi.org/10.1016/j.stem.2013.06.009
67. Hussong JW, Rodgers GM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1):309–313
68. Campioni D, Moretti S, Ferrari L, Punturieri M, Castoldi GL, Lanza F (2006) Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica 91(3):364–368
69. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzii A, Ferrucci PF, Buha R, Lambertenghi-Deliliers G, Pezzella F (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81(8):1398–1401. https://doi.org/10.1038/sj.bjc.6693515
70. Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Montaner B, Chakravarty P, Bhaw L, Duna G, Lassailly F, Gribben J, Bonnet D (2017) Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. Cancer Cell 32(3):324.e6–341.e6. https://doi.org/10.1016/j.ccell.2017.08.001
71. Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S (2016) Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-beta. Stem Cell Investig 3:5. https://doi.org/10.1007/j.iss236-9759.2016.02.03
72. Marisavljevic D, Petrova TV, Svinareva DA, Momotuk KS, Mikhailova EA, Drize NI (2009) Alterations in hematopoietic microenvironment in patients with aplastic anemia. Clin Transl Sci 2(1):67–74. https://doi.org/10.1111/j.1752-8062.2008.00074.x
73. Lu S, Ge M, Zheng Y, Li J, Feng X, Feng S, Huang J, Feng Y, Yang D, Shi J, Chen F, Han Z (2017) CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-kappaB in the bone marrow failure of acquired aplastic anemia. Stem Cell Res Ther 8(1):178. https://doi.org/10.1186/s13287-017-0620-4
74. Hofmberg LA, Seidel K, Leisenring W, Torok-Storb B (1994) Aplastic anemia: analysis of stromal cell function in long-term marrow cultures. Blood 84(11):3685–3690
75. Soenen-Cornu V, Tourino C, Bonnet ML, Guillier M, Flament S, Korb R, Bernstein A, Bourhis JH, Freudhomme C, Fenaux P, Turhan AG (2005) Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene 24(15):2441–2448. https://doi.org/10.1038/sj.onc.1208405
76. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villarom EM, Hernandez-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez-Simon JA, Hernandez-Rivas JM, San-Miguel JF, del Canizo MC (2009) Both expanded and uncultered mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 23(4):664–672. https://doi.org/10.1038/leu.2008.361
77. Flores-Figueroa E, Arana-Trejo RM, Gutierrez-Espindola G, Perez-Cabrera A, Mayani H (2015) Evaluation of bone marrow microvessel density in patients with aplastic anemia. Indian J Hematol Blood Transfus 33(2):169–174. https://doi.org/10.1007/s12288-016-0707-6
78. Goday S, Oz S, Cadeddu RP, Frobel J, Bruckner B, Gundgen A, Fenk R, Bruns I, Zilkens C, Hermens D, Gattermann N, Kobble G, Germin U, Lyko F, Haas R, Schroeder T (2013) Insufficient
Role of the microenvironment in myeloid malignancies

stomal support in MDS results from molecular and cellular deficits of mesenchymal stromal cells. Leukemia 27(9):1841–1851. https://doi.org/10.1038/leu.2013.193

91. Zhao ZG, Xu W, Yu HP, Fang BL, Wu SH, Li F, Li WM, Li QB, Chen ZC, Zou P (2012) Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett 317(2):136–143. https://doi.org/10.1016/j.canlet.2011.08.030

92. Boudard D, Vialet J, Piselli S, Guyotat D, Campos L (2003) In vitro study of stromal cell defects in myelodysplastic syndromes. Haematologica 88(7):827–829

93. Flores-Figueroa E, Montesinos JJ, Flores-Guzman P, Gutierrez-Espindola G, Arana-Trejo RM, Castillo-Medina S, Perez-Cabera A, Hernandez-Estevez E, Arriaga L, Mayani H (2008) Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 32(9):1407–1416. https://doi.org/10.1016/j.leukres.2008.02.013

94. Tennant GB, Walsh V, Truran LN, Edwards P, Mills KI, Burnett AK (2000) Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 111(3):853–862. https://doi.org/10.1046/j.1365-2457.2000.02467x

95. Aanei CM, Flandrin P, Eloae FZ, Carasevici E, Guyotat D, Wattel E, Campos L (2012) Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev 21(10):1604–1615. https://doi.org/10.1007/s10060-011-0390-5

96. Abe-Suzuki S, Kurata M, Abe S, Onishi I, Kirimura S, Nashimoto M, Murayama T, Hidaka M, Kitagawa M (2014) CXCL12 + stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Lab Invest 94(11):1212–1223. https://doi.org/10.3888/labinvest.2014.110

97. Chen S, Zambetti NA, Bindels EM, Kesswill K, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EM, Westers TM, Jansen JH, van de Loosdrecht AA, Raaijmakers MH (2016) Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs. Leukemia 30(9):1938–1942. https://doi.org/10.1038/leukemia.2016.91

98. Bhagat TD, Chen S, Bartenstein BM, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra NA, Mantzaris I, Sukkitha V, Laurence K, Lopez R, Bhagat P, Giricz O, Sohl D, Wisckrema A, Yeung C, Gritsman K, Aplan P, Hochdinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagati A, Boulwood J, Well B, Steidl U, Raaijmakers M, Deeg HJ, Kharas MG, Verma A (2017) Epigenetically aberrant stroma in MDS propagates disease via Wnt/beta-catenin activation. Cancer Res 77(18):4846–4857. https://doi.org/10.1158/0008-5472.CAN-17-0282

99. Pasumarthy KK, Doni Jayavelu N, Kilpinen L, Andrus C, Battle Klaus M, Stavroulaki E, Kastrinaki MC, Fragioiuakki P, Gian 100. Ghazanfari R, Zacharaki D, Li H, Ching Lim H, Soneji S, Schiding S (2017) Human primary bone marrow mesenchymal stromal cells and their in vitro progenies display distinct transcriptional profile signatures. Sci Rep 7(1):10338. https://doi.org/10.1038/s41598-017-09449-x

101. Lanier SL, Korhonen M, Lehenkari P, Lund R, Laitinen S, Hawkins RD (2017) Methylome analysis of human bone marrow MSCs and their in vitro progenies display distinct transcriptional profile signatures. Sci Rep 7(1):10338. https://doi.org/10.1038/s41598-017-09449-x

102. Rouault-Pierre K, Mian SA, Goulard T, Abarrategi A, Tullio AD, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekara AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti cells in patients with myelodysplastic syndromes. Stem Cells Dev 19(7):1043–1054. https://doi.org/10.1089/scd.2009.0286

103. Ferrer RA, Wobus M, List C, Wehner R, Schonefeldt C, Brocard B, Mohr B, Rauver M, Schmitz M, Stehler M, Ehrnh G, Hofbauer LC, Bornhauser M, Platzbecker U (2013) Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 98(11):1677–1685. https://doi.org/10.3324/haematol.2013.083972

104. Kim Y, Jekarl DW, Kim J, Kwon A, Choi H, Lee S, Kim YJ, Kim HJ, Oh IH, Kim M (2015) Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients. Stem Cell Res 14(2):177–184. https://doi.org/10.1016/j.scr.2015.01.004

105. Oliveira FM, Lucena-Araujo AR, Favarin MD, Palma PV, Rego EM, Falcao RP, Covas DT, Fontes AM (2013) Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome; correlation with G-bandning analysis and FISH. Exp Hematol 41(2):198–208. https://doi.org/10.1016/j.exphem.2012.10.009

106. Varga G, Kiss J, Varkonyi J, Vas V, Farkas P, Paloczi K, Uber F (2007) Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 13(4):311–319

107. Fei C, Zhao Y, Guo J, Gu S, Li X, Chang C (2014) Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes. Tumour Biol 35(9):1938–1942. https://doi.org/10.3727/000854713X776581

108. Santamaria C, Muntion S, Roson B, Blanco B, Lopez-Villar O, Carrascio R, Sanchez-Guijo FM, Diaz-Campelo M, Alvarez-Torres I, Sarasaque ME, de las Rivas J, Gonzalez M, San Miguel JF, Del Canizo MC (2012) Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 97(8):1218–1224. https://doi.org/10.3324/haematol.2014.110547

109. Mian SA, Rouault-Pierre K, Smith AE, Seidl T, Pizzitolla I, Kizilors A, Kulasekararaj AG, Bonnet D, Mufti GJ (2015) SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat Commun 6:10004. https://doi.org/10.1038/ncomms10004

110. Medyouf H, Moosner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, Mudder K, Klein C, Olander J, Fey S, Vogler J, Fabarius A, Riedl E, Roehl H, Kohlmann A, Staller M, Haferlach C, Muller N, John T, Platzbecker U, Metzgeroth G, Hofmann WK, Trump P, Nowak D (2014) Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14(6):824–837. https://doi.org/10.1016/j.stem.2014.02.014

111. Rouault-Pierre K, Mian SA, Goulard T, Abarrategi A, Tullio AD, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti

 Springer
Martinaud C, Desterke C, Konopacki J, Pieri L, Torossian F, Renault E, Pierre-Louis O, Souraud JB, de Revel T, Dupriez B, Ianotto JC, Bourgeade MF, Vannucchi AM, Lataillade JJ, Le Bousse-Kerdiles MC (2015) Osteogenic potential of mesenchymal stromal cells contributes to primary myelofibrosis. Cancer Res 75(22):4753–4765. https://doi.org/10.1158/0008-5472.CAN-14-3696

Schneider RK, Ziegler S, Leisten I, Ferreira MS, Schumacher A, Rath B, Fahrenkamp D, Muller-Newen G, Cryands M, Willop S, Jost E, Koschmieder S, Knuchel R, Brummendorf TH, Ziegler P (2014) Activated fibroblast-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms. J Hematol Oncol 7:92. https://doi.org/10.1186/s13045-014-0092-2

Manshouri T, Estrov Z, Quintas-Cardama A, Burger J, Leboulenger B, Ianotto JC, Bourgeade MF, Vannucchi AM, Lataillade JJ, Pierre-Louis O, Souraud JB, de Revel T, Dupriez B, Le Bousse-Kerdiles MC (2015) Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis. Haematologica 100(6):757–767. https://doi.org/10.3324/haematol.2014.118497

Asgouni D, Tosca L, Sorel N, Bonnet ML, Dkhissi F, Tachtjian G, Bennaceur-Griscelli A, Chomel JC, Turhan AG (2014) Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. Oncoscence 1(1):57–68. https://doi.org/10.1016/j.exphem.2006.04.002

Vianello F, Villanova F, Tisato V, Lympieri S, Ho KK, Gomes AR, Marin D, Bonnet D, Apperley J, Lam EW, Dazzi F (2010) Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 95(7):1081–1089. https://doi.org/10.3324/haematol.2010.118278

Gunsilius E, Duba HC, Petzer AL, Kahmer CM, Grunewald K, Stockhammer G, Gabi C, Dirnhofer S, Clausen J, Gastl G (2000) Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355(9216):1688–1691. https://doi.org/10.1016/S0140-6736(00)02241-8

von der Heide EK, Neumann M, Vosberg S, James AR, Schroeder MP, Ortiz-Tanche J, Isaakidis K, Schlee C, Luther M, Johrens K, Anagnostopoulos I, Mochmann LH, Nowak D, Hofmann WK, Greif PA, Baldus CD (2016) Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients. Leukemia. https://doi.org/10.1038/leu.2016.324

Geyh S, Rodriguez-Paredes M, Jager P, Khandanpour C, Cadeddu RP, Gutekunst J, Wilk CM, Fenk R, Zilkens C, Hermens D, Gerner U, Kobbe G, Lyko F, Haas R, Schroeder T (2015) Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia 30(3):683–691. https://doi.org/10.1038/leu.2015.325

Chandran P, Le Y, Li Y, Sabloff M, Mehrig J, Rosu-Myles M, Allan DS (2015) Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leuk Res 39(4):486–493. https://doi.org/10.1016/j.leukres.2015.01.013126

Zhao ZG, Liang Y, Li K, Li WM, Li QB, Chen ZC, Zou P (2007) Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 16(4):637–648. https://doi.org/10.1089/scd.2007.0008

Abdel-Aziz AM, Shaﬁat MS, Mehta TK, Di Palma F, Lawes MJ, Rushworth SA, Bowles KM (2016) MIF-induced stromal PKCbeta/IL8 is essential in human acute myeloid leukemia. Cancer Res 77(2):303–311. https://doi.org/10.1158/0008-5472.CAN-16-1095

Takam Kamga P, Bassi G, Cassaro A, Midolo M, Di Trapani M, Gattì A, Carusone R, Resci F, Perbellini O, Gottardi M, Bonifacio M, Nwabo Kamdjé AH, Ambrosetti A, Krampera M (2016) Notch signalling drives bone marrow stem cell-mediated chemoresistance in acute myeloid leukemia. Oncotarget 7(16):21713–21727. https://doi.org/10.18632/oncotarget.7964

Flores-Figueroa E, Varma S, Montgomery K, Greenberg PL, Gratzinger D (2012) Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myeloproliferative bone marrow. Lab Invest 92(9):1330–1341. https://doi.org/10.1038/lscl.2012.93

Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, Turkmen S, Benlasfer O, Schumann E, Sindram A, Mokkentin M, Mundlos S, Keilholz U, Thiel E, Blau IW (2011) Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 118(20):5583–5592. https://doi.org/10.1182/blood-2011-03-343467

Dar A, Kollet O, Lapidot T (2006) Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 34(8):967–975. https://doi.org/10.1016/j.exphem.2006.04.002

Zhang Y, Patel S, Abdelouahab H, Wittner M, Willekens C, Shen S, Betens A, Jolvin V, Opolon P, Bawa O, Pasquier F, Ito M, Fujii N, Goinin P, Solary E, Vainchenker W, Coppo R, De Bontron S, Louache F (2012) CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis 3:e396. https://doi.org/10.1038/cddis.2012.137

Abraham M, Klein S, Bulvix B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjaminsi O, Nagler A, Pereg Y, Tavor S, Peled A (2017) The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia. https://doi.org/10.1038/leu.2017.82

Ding L, Morrison SJ (2013) Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495(7440):231–235. https://doi.org/10.1038/nature11885

Greenbaum A, Hsu YM, Day RB, Schuettelz LG, Christopher MJ, Borgerding JN, Nagasawa T, Link DC (2013) CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495(7440):227–230. https://doi.org/10.1038/nature11926

Kim JA, Shim JS, Lee GY, Yim HW, Kim TM, Kim M, Leem SH, Lee JW, Min CK, Oh IH (2015) Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer
Role of the microenvironment in myeloid malignancies

Res 75(11):2222-2231. https://doi.org/10.1158/0008-5472.CAN-14-3379
136. Diaz de la Guardia R, Lopez-Millan B, Lavoie JR, Bueno C, Castano J, Gomez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menendez P (2017) Detailed characterization of mesenchymal stem/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Rep 8(6):1573-1586. https://doi.org/10.1016/j.stemcr.2017.04.019

137. Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnyal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpali E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RM, Harrington MA, Cahill CW, Bueso-Ramos C, Andreff M (2017) AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemogenesis. JCI Insight. https://doi.org/10.1172/jci.insight.90036

138. Boyd AL, Reid JC, Salci KR, Aslostovar L, Benoit YD, Shapovalova Z, Nakanishi M, Porras DP, Almakadi M, Campbell CJV, Jackson MF, Ross CA, Foley R, Allan DS, Sabloff M, Xenocostas A, Collins TJ, Bhatia M (2017) Acute myeloid leukemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nat Cell Biol 19(11):1336-1347. https://doi.org/10.1038/ncb3625

139. Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel E, Rosu-Myles M, Menendez P, Castano J, Gomez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpali E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RM, Harrington MA, Cahill CW, Bueso-Ramos C, Andreff M (2017) Detailed characterization of mesenchymal stem/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Rep 8(6):1573-1586. https://doi.org/10.1016/j.stemcr.2017.04.019

140. Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, Strunk D, Hofmann NA, Reinisch A, Konopleva M, Andreeff M (2012) Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 119(21):4971-4980. https://doi.org/10.1182/blood-2011-09-548941

141. Abarrategi A, Foster K, Hamilton A, Mian SA, Passaro D, Gribbien J, Mufti G, Bonnet D (2017) Versatile humanized niche model enables study of normal and malignant human hematopoiesis. J Clin Invest 127(2):543-548. https://doi.org/10.1172/JCI89364

142. Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GI, Martens AC, Vellenga E, Groen RW, Schuringa JJ (2016) Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. Blood 128(25):2949-2959. https://doi.org/10.1182/blood-2016-05-719021

143. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, Majeti R (2016) A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med 22(7):812-821. https://doi.org/10.1038/nm.4103

144. Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arolot LT, Ladbury JE, Burks JK, Kornblau S, Andreff M (2016) Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFkappaB/IL1beta signaling network. Oncotarget 7(15):20054-20067. https://doi.org/10.18632/oncotarget.7911

145. Yi H, Zeng D, Shen Z, Liao J, Wang X, Liu Y, Zhang X, Kong P (2016) Integrin alphavbeta3 enhances beta-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for micro-environment influence on sorafenib sensitivity. Oncotarget 7(26):40387-40397. https://doi.org/10.18632/oncotarget.9617

146. Chen P, Huang H, Wu J, Lu R, Wu Y, Jiang X, Yuan Q, Chen Y (2014) Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis. Mol Carencing 54(12):1678-1685. https://doi.org/10.1002/mc.22239

147. Griessinger E, Anjos-Afonso F, Pizzitola I, Rouault-Pierre K, Vargafig J, Taussig D, Gribben J, Lassailly F, Bonnet D (2014) A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl Med 3(4):520-529. https://doi.org/10.5966/sctm.2013.0166

148. Reikvam H, Brenner AK, Hagen KM, Liseth S, Skrede S, Hatfield KJ, Brusserd O (2015) The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res 15(3):530-541. https://doi.org/10.1016/j.scr.2015.09.008

149. Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A, Yoshizato T, Hirsch C, Przychodzen B, Mahfouz RZ, Kuzmanovic T, Sekeres MA, Makishima H, Ogawa S, Maciejewski JP (2017) Origins of myelodysplastic syndromes after aplastic anemia. Blood. https://doi.org/10.1182/blood-2017-02-767731

150. Uy GL, Retting MP, Motabi IH, McFarland K, Trinkaus KM, Thirumala KS, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF (2012) A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukaemia. Blood 119(17):3917-3924. https://doi.org/10.1182/blood-2011-10-383406

151. Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopenopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreff M, Konopleva M (2015) Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood 126(2):222-232. https://doi.org/10.1182/blood-2015-02-628677

152. Verma D, Krause DS (2017) Targeting the bone marrow niche in hematological malignancies. In: Bonnet D (ed) Advances in stem cells and their niches, vol 1. Elsevier, Academy of Press, Cambridge, MA, pp 155-169

153. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110(50):20212-20217. https://doi.org/10.1073/pnas.1320318110